Abbott Reports Postmarket Data on its MitraClip System

Abbott presented positive data from a postmarket study of its MitraClip G4 heart valve repair device at the Transcatheter Cardiovascular Therapeutics annual scientific symposium in Boston.

The MitraClip G4, which was approved by the FDA in 2019, is the fourth-generation of the company’s MitraClip device first approved by the FDA in 2013. The mitral valve regurgitation repair system is delivered to the heart through a small incision in the leg.

In the postmarket study, the MitraClip G4 led to a significant reduction in mitral regurgitation in 91 percent of patients, the company said.

Earlier this month, Abbott issued a recall notice for all versions of its MitraClip clip delivery system citing a risk of a malfunctioning clip.